Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 4/20 | 0.49 |
| ▸ | EHMT1 | Q9H9B1 | 4/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.47 |
| ▸ | AXL | P30530 | 3/20 | 0.46 |
| ▸ | MET | P08581 | 13/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | MST1R | Q04912 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1895448 | 0.99 | EHMT2 (0.48) | EHMT2EHMT1FGFR2AXLMET | |
| SCHEMBL14540831 | 0.92 | AXL (0.56) | FGFR2AXLMETEGFRRET | |
| SCHEMBL14540655 | 0.87 | EHMT2 (0.47) | EHMT2EHMT1FGFR2AXLMET | |
| SCHEMBL14540559 | 0.84 | AXL (0.43) | FGFR2AXLMETKITKDR | |
| SCHEMBL12411211 | 0.84 | EHMT2 (0.49) | EHMT2EHMT1FGFR2AXLMET | |
| SCHEMBL14540577 | 0.84 | FGFR2 (0.51) | FGFR2AXLMET | |
| SCHEMBL14609460 | 0.84 | FGFR2 (0.51) | FGFR2AXLMET | |
| SCHEMBL14540569 | 0.84 | AXL (0.41) | FGFR2AXLMETKITKDR | |
| SCHEMBL12411209 | 0.83 | FGFR2 (0.50) | EHMT2EHMT1FGFR2AXLMET | |
| SCHEMBL1895977 | 0.83 | AXL (0.45) | FGFR2AXLMETKITKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372981-B2 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-02-12 | — | — | US | disclosed |
| US-8372981-B2 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-02-12 | — | — | US | disclosed |
| US-7973160-B2 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-7973160-B2 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20110118470-A1 | NITROGEN-CONTAINING AROMATIC DERIVATIVES | FUNAHASHI YASUHIRO | 2011-05-19 | — | — | US | disclosed |
| US-20110118470-A1 | NITROGEN-CONTAINING AROMATIC DERIVATIVES | FUNAHASHI YASUHIRO | 2011-05-19 | — | — | US | disclosed |
| US-20100197911-A1 | Nitrogen-Containing Aromatic Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100197911-A1 | Nitrogen-Containing Aromatic Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-7612092-B2 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-7612092-B2 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-7253286-B2 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI CO., LTD (JP) | 2007-08-07 | — | — | US | disclosed |
| EP-1777218-A1 | Process for the preparation of 4-phenoxy quinoline derivatives | Eisai R&D Management Co., Ltd. (JP) | 2007-04-25 | — | — | EP | disclosed |
| EP-1777218-A1 | Process for the preparation of 4-phenoxy quinoline derivatives | Eisai R&D Management Co., Ltd. (JP) | 2007-04-25 | — | — | EP | disclosed |
| EP-1415987-B1 | NITROGENOUS AROMATIC RING COMPOUNDS AS ANTI CANCER AGENTS | EISAI R&D MAN CO LTD (JP) | 2007-02-28 | — | — | EP | disclosed |
| EP-1415987-B1 | NITROGENOUS AROMATIC RING COMPOUNDS AS ANTI CANCER AGENTS | EISAI R&D MAN CO LTD (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-20060247259-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-11-02 | — | — | US | disclosed |
| US-20060160832-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1506962-A2 | Nitrogen-containing aromatic heterocycles | Eisai Co. Ltd. (JP) | 2005-02-16 | — | — | EP | disclosed |
| EP-1415987-A1 | NITROGENOUS AROMATIC RING COMPOUNDS | Eisai Co., Ltd. (JP) | 2004-05-06 | — | — | EP | disclosed |
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197911-A1 | Nitrogen-Containing Aromatic Derivatives | GNG2, GCG, FRG1 | EHMT2 1107/4885EHMT1 1232/4885FGFR2 969/4885 |
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | VEGFA, UACA, UTS2R | EHMT2 1691/4885EHMT1 1512/4885FGFR2 681/4885 |
| US-20060247259-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | UGGT1, FLT1, GCG | EHMT2 1800/4885EHMT1 1737/4885FGFR2 1925/4885 |
| US-20110118470-A1 | NITROGEN-CONTAINING AROMATIC DERIVATIVES | GNG2, GCG, FRG1 | EHMT2 1206/4885EHMT1 1275/4885FGFR2 1118/4885 |
| US-20060160832-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | UGGT1, FLT1, GCG | EHMT2 1800/4885EHMT1 1737/4885FGFR2 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.